Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

FGL (FG Loop Peptide) peptide icon, one bubble per amino acidFGL (FG Loop Peptide)15 residuesEVYVVAENQQGKSKAEach bubble = one amino acid. Size = residue mass. Color = chemical class.

FGL (FG Loop Peptide)

Beginner tier: 1 mg, 5x/week · preclinical extrapolation

CognitivePhase 1
~4-6 hours half-life·Injection

Also known as: FGL, FGLL, FG Loop peptide

Twenty-four volunteers. One Phase I trial. Then the entire clinical program shut down in 2014. FGL is a 15-amino-acid synthetic peptide that mimics NCAM's binding region on fibroblast growth factor receptor 1 (FGFR1). In rodent studies, it protects hippocampal neurons from ischemic death and boosts long-term potentiation in the dentate gyrus for up to 24 hours. Community subcutaneous doses of 1 to 2 mg sit 10 to 100 times below the Phase I intranasal doses that actually reached the brain. Early adopters chasing cognitive gains should know the dose-response gap is real.

What Is FGL (FG Loop Peptide)?

FGL (FG Loop peptide) is a synthetic pentadecapeptide corresponding to residues E681 through A695 of NCAM's second fibronectin type III module. Whether it actually reaches the brain at the doses people inject remains the open question. The active form is FGL(L), a dimerized version of the monomer with better blood-brain barrier penetration. It was designed to mimic the NCAM-FGFR1 binding interaction, making it a targeted FGFR1 agonist.

The preclinical track record is genuinely strong. Klementiev and colleagues [1] showed that a single injection after training produced memory improvements lasting a full month in rats. Bhatt's group confirmed hippocampal CA1 neuron protection against ischemic damage [2]. The Phase I intranasal trial (n=24)[3] used doses of 25, 100, and 200 mg and confirmed tolerability with detectable brain penetration.

The disconnect: community subcutaneous dosing runs 1 to 2 mg daily. Phase I intranasal doses ran 25 to 200 mg. That is a 12x to 200x gap. No human subcutaneous pharmacokinetic study exists. Whether 1 to 2 mg SC even reaches the CNS in meaningful amounts is genuinely unknown.

Fewer than 30 people have shared their experiences online. Longecity thread #109111 contains about 15 to 20 individual reports with mixed outcomes. Clinical development ended when the NeuroFGL consortium (CORDIS #278006) failed to advance past Phase I by 2014.

How FGL (FG Loop Peptide) Works

FGL binds directly to fibroblast growth factor receptor 1 (FGFR1), mimicking the natural contact between NCAM's second fibronectin type III domain and the receptor. That binding triggers FGFR1 phosphorylation and splits signaling down two paths.

The first is the Ras-MAPK cascade. This arm drives neurite outgrowth, neuronal differentiation, and synaptic remodeling. Rodent studies confirmed increased synaptophysin expression within 24 to 72 hours of dosing [4].

The second is the PI3K-Akt pathway. This promotes neuronal survival by suppressing pro-apoptotic signals. In hippocampal slice cultures exposed to oxygen-glucose deprivation, FGL preserved metabolic function and presynaptic activity whether applied before or after the insult [2].

At the synapse, FGL activates PKC signaling. PKC triggers activity-dependent delivery of AMPA receptors to postsynaptic membranes. More AMPA receptors at the synapse means stronger signal transmission; this is the molecular basis for its memory-consolidating effects.

FGL also mobilizes endogenous neural stem cells from the subventricular zone and hippocampus after stroke, supporting remyelination and modulating neuroinflammation through microglial regulation [5]. The active clinical form is FGL(L), a dimerized version of two monomers linked together. The dimer provides better blood-brain barrier penetration.

FGL (FG Loop Peptide) Benefits

  • FGL benefits center on neuroprotection, synaptic plasticity, and cognitive support in preclinical models.
  • Hippocampal neuroprotection: a single suboccipital injection protected CA1 neurons from ischemic death in rodent global ischemia models [2].
  • Memory consolidation lasting up to one month after a single intracerebroventricular dose in rat fear conditioning and water maze tasks [1]. That persistence surprised the original researchers.
  • First peptide shown to produce in vivo long-term potentiation in the dentate gyrus of freely moving rats, with effects lasting 24 hours [6].
  • Neurite outgrowth confirmed across three neuronal types: dopaminergic, hippocampal, and cerebellar neurons showed increased process formation after FGL exposure [4].
  • Post-stroke neural stem cell mobilization from the subventricular zone and hippocampus, plus remyelination support and microglial modulation [5].
  • Some Longecity users report subjective improvements in verbal recall and mental clarity by weeks 3 to 4, though total reports number below 30 and can't be separated from placebo.

FGL (FG Loop Peptide): Science vs Community Consensus

Science Only
Scientific Evidence
Weak
Based on 8 key studies·Phase 1

Phase I-only human data (intranasal, single-dose, n=24, 2007).

Dosing studied: Human: 25–200 mg intranasal (Phase I safety only: tolerability endpoint, not efficacy). Animal: 2–10 mg/kg SC/ICV for cognitive/LTP effects. Community SC protocol (1–2 mg/day) is unvalidated by any human or allometrically-scaled data.
Read the evidence (key study, limitations)

Clinical development abandoned 2014 after NeuroFGL EU consortium failed to advance to Phase 2a. No Phase 2 conducted. Strong preclinical evidence for neuroprotection, LTP, and neurogenesis, but zero human efficacy data exists. Pro-epileptogenic signal in mouse kindling model is a real safety concern.

Key Study

Bhatt DL et al. 2007 (PMID 17375985): Phase I intranasal FGL(L) in 24 healthy volunteers at 25, 100, 200 mg. All doses tolerated; mild nasal burning at 200 mg (2 subjects, <3 min). Dose-proportional systemic exposure; brain penetration detected. 8-day observation only: no chronic safety data.

Limitations

No human efficacy data. Single Phase I trial (n=24, single dose, intranasal, 8-day observation only). Clinical development discontinued 2014: no Phase 2 attempted or planned. Community SC protocol (1–2 mg/day) is 10–100× below Phase I intranasal doses with no human PK basis. Pro-epileptogenic signal: FGL at 2 and 10 mg/kg SC significantly lowered generalized seizure threshold in mouse kindling model (PMC3963124). FGFR1 agonism is a theoretical oncogenesis risk (FGFR1 amplified/mutated in ~5–10% of human cancers). Must use dimerized FGL(L) form: monomer has inferior CNS penetration.

Community Experience
Weak
2.0/5
Based on <5 Reddit threads

Extremely limited community experience.

Community dosing: 1–2 mg/day SC (5 days on / 2 days off), 6-week cycles: entirely from Dr. Seeds' Peptide Protocols Vol 1. No community consensus distinct from this single-source protocol.
Read the reports (what users report 4, common issues 5)

Fewer than 5 Reddit threads across r/Nootropics and r/Peptides. Primary data from Longecity forum thread #109111. Theoretical enthusiasm (FGFR1 mechanism, LTP, neuroprotection) exceeds actual user reports. Mixed outcomes: occasional cognitive clarity reports alongside brain fog and mood dysregulation.

What users report (4)
  • Occasional cognitive clarity and improved verbal recall (Longecity enthusiasts)
  • Theoretically compelling FGFR1/LTP mechanism, well-supported in animal literature
  • Neuroprotective potential discussed favorably for TBI/stroke recovery
  • Some users report subjective post-cycle persistence of benefits
Common issues (5)
  • Brain fog and mood dysregulation reported by multiple Longecity users
  • Dose-response completely unclear: community doses likely far below CNS-effective range
  • Essentially no reproducible community evidence base: too few users to draw conclusions
  • Seizure risk concern poorly understood in community
  • High cost (~$360/cycle) for an unvalidated SC protocol
Science-Only Evidence

Science establishes neuroprotective and LTP-enhancing effects in well-controlled rodent studies. Community adoption is too minimal and dose-uncertain to validate or refute the science. The community SC protocol (1–2 mg/day) may be producing no meaningful CNS effect: making both positive and negative community outcomes uninformative about the true mechanism.

FGL (FG Loop Peptide) Dosage Guide

ExtrapolatedDose extrapolated from Phase 1 safety study; clinical dosing protocol not established
LevelDose / InjectionFrequency
Beginner1 mg
5x/weekTrack
Moderate1.5 mg
5x/weekTrack
Aggressive2 mg
5x/weekTrack
Note:

The single most important thing: confirm your product is dimerized FGL(L), not the monomer. The monomer has inferior CNS penetration and is the wrong form entirely. The CoA should specify dimeric form and molecular weight around 3,476 Da.

Reconstitution math for a 5 mg vial: add 2 mL bacteriostatic water to get 2.5 mg/mL. A 1 mg dose is 0.4 mL, which is 40 units on a U-100 insulin syringe. A 2 mg dose is 0.8 mL (80 units). For a 10 mg vial with 2 mL BAC water, you get 5 mg/mL. A 2 mg dose becomes 0.4 mL (40 units).

Swirl gently for 15 or more minutes after adding water. FGL(L) is stubborn to dissolve. If you see particles that won't clear, discard the vial.

HA-FGL (about $122 per vial) is a hyaluronic acid conjugate. Different compound entirely with zero published human data. Not interchangeable with FGL(L).

Cycling Protocol

On Period
6 weeks
Off Period
4 weeks

Standard protocol is 5 days on, 2 days off for 6 weeks. Evaluate cognitive response before continuing. Some practitioners recommend 4 weeks off between cycles to maintain receptor sensitivity.

Calculate your FGL (FG Loop Peptide) dose
Free dosage calculator with syringe visualization

Or use the universal Peptide Calculator for any peptide.

FGL (FG Loop Peptide) Protocols by Goal

beginnerCommunity6 weeks on, 4 weeks off
Titration
Wk 1–2
1 mg · 5 days/week (Monday–Friday) · Subcutaneous
Maintenance
Wk 3–6
2 mg · 5 days/week (Monday–Friday) · Subcutaneous

Expected: Anecdotal: possible improvements in focus, verbal recall, and memory consolidation by weeks 3–6. No human efficacy data exists to validate these outcomes. Dose adequacy for CNS effects in humans is unknown.

Monitor: Weekly mood/cognition self-check. Any seizure-like symptoms (head sensations, visual disturbances, muscle twitching): stop immediately. Confirm the product is dimerized FGL(L) before use.

How to Use FGL (FG Loop Peptide)

  1. 1
    Step 1

    Pull 2 mL of bacteriostatic water into a syringe and inject it slowly into your 5 mg FGL(L) vial. Aim the stream against the glass wall, not directly onto the powder.

  2. 2
    Step 2

    Swirl the vial gently for 15 minutes or until fully dissolved. Don't shake or vortex. If cloudiness or particles persist after 15 minutes, discard the vial.

  3. 3
    Draw your dose using a U-100 insulin syringe

    From a 5 mg/2 mL vial: 1 mg equals 40 units (0.4 mL). From a 10 mg/2 mL vial: 2 mg equals 40 units (0.4 mL).

  4. 4
    Step 4

    Pinch abdominal fat and inject subcutaneously at a 45-degree angle. Use a 29 to 31 gauge needle. Rotate injection sites daily.

  5. 5
    Dose in the morning

    Follow the 5-days-on, 2-days-off schedule (Monday through Friday).

  6. 6
    Start at 1 mg daily for weeks 1 to 2

    Move to 1.5 to 2 mg only if you tolerate the starting dose without brain fog, mood changes, or neurological symptoms.

  7. 7
    Store reconstituted vials at 2 to 8 degrees C

    Use within 21 days. Do not freeze after reconstitution. Lyophilized vials keep at minus 20 degrees C for up to 24 months.

Alternative Routes

Intranasal

Phase I intranasal doses: 25–200 mg. Community SC doses: 1–2 mg. Routes are not interchangeable: Phase I doses are 12–200× higher than community SC doses.

The only human data (PMID 17375985) used intranasal FGL(L) at 25, 100, and 200 mg. Some community members are experimenting with intranasal FGL at 1–5 mg as a compromise for direct CNS delivery, but this has no clinical validation. Mild nasal burning reported in 2/8 subjects at 200 mg in Phase I is not expected at lower doses.

Mixing your own vial? Use the FGL (FG Loop Peptide) reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

FGL (FG Loop Peptide) Stacking Protocols

Works With

Avoid

Dihexa

Both are FGFR1 agonists. Concurrent use risks additive FGFR1 signaling: oncogenesis risk theoretically compounded and seizure threshold potentially further lowered. No combination data exists in any species. Dihexa also has two foundational mechanism papers retracted (April 2025, data fabrication).

Do not combine
FGFR inhibitors (erdafitinib, pemigatinib, infigratinib)

Direct pharmacodynamic antagonism: FGFR inhibitors block FGL's receptor-mediated effects entirely. No combination data, but mechanism predicts complete antagonism.

Do not combine
Anticonvulsant medications (levetiracetam, lamotrigine, valproate)

Caution: FGL may reduce effective anticonvulsant coverage by lowering seizure threshold (PMC3963124). Do not initiate FGL in patients actively managed for seizure disorders.

Active malignancy treatment regimens (FGFR1-driven cancers)

FGFR1 is an oncogenic driver in ~5–10% of all human cancers (breast, lung, bladder, endometrial). FGL agonism could theoretically worsen FGFR1-amplified malignancies. Absolute contraindication in any active malignancy.

Do not combine

Estimated Cost

Generic / Research
FGL(L) 10 mg vial: ~$120 (research-grade listing). Per-cycle cost at 2 mg SC × 5 days/week × 6 weeks = ~60 mg total = 6 × 10 mg vials = ~$720/cycle. At 1 mg/day × 5 days/week × 6 weeks = ~30 mg = 3 vials = ~$360/cycle.

Pricing updated 2026-04-09

FGL (FG Loop Peptide) Side Effects

The seizure risk is the lead concern. In a mouse kindling model of epilepsy, FGL at 2 and 10 mg/kg subcutaneous lowered the stimulation threshold for generalized seizures (PMC3963124). This is not a theoretical flag. It is a published preclinical finding that directly contradicts casual use in anyone with a seizure history.

The Phase I human data covers 24 volunteers receiving single intranasal doses of 25, 100, or 200 mg of FGL(L) [3]. Two of eight subjects at the 200 mg dose reported brief nasal burning lasting less than 3 minutes. No ECG abnormalities, no vital sign changes, no laboratory parameter shifts across any dose group. That is reassuring for single-dose safety, but 8 days of observation in 24 people tells you almost nothing about chronic subcutaneous use.

FGFR1 carries an oncogenesis concern. FGFR1 is amplified or mutated in roughly 5 to 10 percent of human cancers, including breast, lung, bladder, and endometrial malignancies. Sustained FGFR1 agonism could theoretically worsen any FGFR1-driven tumor. No cancer events appeared in the Phase I trial, but single-dose exposure is a poor test of this risk. Active malignancies are an absolute contraindication.

Community side effects from the small Longecity user base include brain fog, mood dysregulation, and cognitive dulling, particularly in the first two weeks. These come from fewer than 30 total reports, so frequency estimates are not possible.

An important caveat about community side effects: the subcutaneous doses people use (1 to 2 mg) may be far below CNS-effective concentrations. Allometric scaling of the animal doses (2 to 10 mg/kg in rats) translates to 140 to 700 mg for a 70 kg human. Both positive and negative community outcomes may be noise rather than real pharmacological signal.

Injection site discomfort is mild and transient. Reconstitution can be tricky; FGL(L) dissolves slowly, and cloudy solutions with persistent particulate should be discarded.

Contraindications: pregnancy and breastfeeding (no reproductive safety data). Seizure disorders or epilepsy history. Active brain tumors or CNS malignancies. Known hypersensitivity to NCAM-derived peptides. Children under 18.

When to stop: any seizure-like symptoms including unusual head sensations, visual disturbances, or muscle twitching. Mood disruption persisting beyond one week. Any new cancer diagnosis.

Common Issues & Solutions

Brain fog or cognitive dulling in first 1–2 weeks: may indicate individual sensitivity: reduce to 0.5 mg/day and reassess before discontinuing. FGL's ~4–6h half-life means rapid clearance; symptoms typically resolve within 24h of dose reduction.

No perceivable effect after 4 weeks at 1–2 mg SC: dose is likely below CNS-effective threshold. Allometric scaling of preclinical effective doses (2–10 mg/kg in rats) translates to 140–700 mg for a 70 kg human: orders of magnitude above community doses. Consider whether the protocol is appropriate; increasing SC dose further lacks safety basis.

Using monomer instead of dimerized FGL(L): the monomer is the wrong form. FGL(L) bivalent structure is required for effective NCAM-FGFR1 mimicry and CNS penetration. Verify the product is the dimerized form before attributing lack of effect to dose.

Reconstitution clouding or visible particulate: FGL(L) can be poorly soluble. Allow 15+ minutes of gentle swirling (no vortexing) after adding bacteriostatic water. If particulate persists, discard vial: do not inject.

HA-FGL vs FGL(L) confusion: "HA-FGL" is a hyaluronic acid-conjugated product: a chemically distinct compound with no published human data. It is NOT interchangeable with FGL(L). Check the exact product specification before use.

Ask AI about this page

Ask AI for a second opinion on FGL (FG Loop Peptide) dosing and side effects

Contraindications

  • Pregnancy and breastfeeding (insufficient human safety data)
  • History of seizure disorders or epilepsy (preclinical data suggests possible lowered seizure threshold)
  • Known hypersensitivity to FGL or NCAM-derived peptides
  • Active brain tumors or CNS malignancies (FGFR1 activation may promote cell proliferation)
  • Children under 18 (limited pediatric safety data in humans)

Drug Interactions

  • FGFR inhibitors (e.g., erdafitinib, pemigatinib) may directly antagonize FGL effects
  • Anticonvulsant medications: monitor closely given preclinical seizure threshold concerns
  • Other neurotrophic peptides (Cerebrolysin, Dihexa): potential additive effects; use caution with combination protocols
  • No formal drug interaction studies have been conducted in humans
  • Direct pharmacodynamic antagonism: FGFR inhibitors block FGL's receptor-mediated effects entirely. No combination data, but mechanism predicts complete antagonism.
  • Active malignancy treatment regimens (FGFR1-driven cancers)

Product Quality

Recommended Monitoring

TestWhenTarget
Neurological self-assessmentWeekly throughout protocolNo new neurological symptoms; stable or improving mood baseline
Liver function tests (ALT, AST, bilirubin)Baseline and at cycle end (week 6)Within normal laboratory reference ranges
Cognitive self-assessment (memory, verbal fluency)Weekly using consistent test (digit span, verbal recall)Not listed
Neurological self-assessment

Early detection of mood changes, cognitive disruption, or prodromal seizure symptoms. FGL's preclinical pro-epileptogenic signal (PMC3963124) warrants routine self-monitoring for unusual head sensations, visual disturbances, or muscle twitching.

Liver function tests (ALT, AST, bilirubin)

Precautionary monitoring for any novel peptide with CNS growth factor signaling. No hepatotoxicity data exists for chronic SC FGL dosing.

Cognitive self-assessment (memory, verbal fluency)

Objective tracking of any cognitive signal: positive or negative. Identifies non-responders before completing full 6-week cycle. Also catches early cognitive worsening.

FGL (FG Loop Peptide) Before and After

Week 1

Minimal noticeable effects. The peptide begins engaging FGFR1 signaling and initiating synaptic remodeling processes. Some users report subtle improvements in mental clarity.

Weeks 2-3

Gradual improvements in focus, verbal recall, and working memory. Synaptic plasticity changes are building as AMPA receptor trafficking increases.

Weeks 4-6

Peak cognitive benefits typically emerge. Noticeable improvements in memory consolidation, learning speed, and mental endurance.

Weeks 7-10
off-cycle

Benefits often persist beyond the active dosing period due to structural synaptic changes and ongoing neurotrophic factor upregulation.

What to Expect

Week 1: Most people won't notice anything. FGFR1 phosphorylation and downstream MAPK/PI3K signaling begin at the cellular level, and synaptophysin upregulation appears within 24 to 72 hours in preclinical models. Structural synaptic changes take weeks to build. Some users report subtle mental clarity; distinguishing that from placebo with single-user anecdotes is basically impossible. Common side effects: mild injection site discomfort, occasional headache, and brain fog reported by a minority at 2 mg doses.

Weeks 2 to 3: This is when a signal starts building, if one appears at all. Rodent studies showed detectable LTP improvements in the dentate gyrus by week 2 [6]. AMPA receptor trafficking increases with continued FGFR1 activation. A subset of Longecity users report improved verbal recall and mental clarity in this window. Many report nothing. Mood changes (positive or negative) surface for some users here.

Weeks 4 to 6: Peak claimed benefit window. Positive responders (a minority) describe improved memory consolidation, learning speed, and mental endurance. The animal data comes from ICV administration, and community SC doses are unlikely to reach ICV-equivalent CNS concentrations. Negative responders still report ongoing brain fog or mood disruption. Fatigue shows up for some users toward cycle end.

Weeks 7 to 10 (off-cycle): Structural synaptic changes from FGFR1-mediated remodeling may outlast active dosing. Animal ICV studies showed benefit persistence four weeks post-administration. A few Longecity users claim sustained cognitive benefits two to four weeks after stopping. Based on very few reports; reliability is low.

Detailed Timeline: Science vs Community

Week 1
Science

FGFR1 phosphorylation and MAPK/PI3K cascade activation begin with first dose. Preclinical studies show synaptophysin upregulation within 24–72h. Structural synaptic changes require weeks.

Community

Most users report nothing notable in week 1. Occasional "mental clarity" reports are difficult to distinguish from placebo given single-user anecdote quality.

Weeks 2–3
Science

LTP improvements in dentate gyrus detectable by week 2 in rodents (PMID 21508096). AMPA receptor trafficking increases with continued FGFR1 activation. Memory consolidation effects emerged in weeks 2–4 in rodent fear-conditioning and water-maze models.

Community

A subset of Longecity users report improved verbal recall and mental clarity starting week 2–3. Effect onset is inconsistent; many users report no effect through week 3.

Weeks 4–6
Science

Cumulative synaptic remodeling: animal memory improvements persisted up to 1 month post-injection after ICV administration. Community SC dosing is unlikely to achieve ICV-equivalent CNS exposure; extrapolation uncertain.

Community

Positive responders (a minority) report best cognitive results: improved memory consolidation, learning speed, mental endurance. Negative responders report ongoing brain fog or mood disruption.

Weeks 7–10 (off-cycle)
Science

Structural synaptic changes from FGFR1-mediated remodeling may outlast active dosing. Animal ICV studies showed benefit persistence 4 weeks post-administration. Whether SC human dosing replicates this is unknown.

Community

Some Longecity users report sustained subjective benefits 2–4 weeks post-cycle. Based on very few reports; not reliable.

Pharmacokinetics

Half-Life
5h
Bioavailability
SC: detectable in plasma and CSF; intranasal 200 mg yields Cmax 1.38 ng/mL
Tmax
~1-2 hours (subcutaneous); ~1 hour (intranasal)
Data Confidence
low

Source: Estimated 4-6 hours following subcutaneous administration; CSF concentrations stable up to 5 hours post-injection in rats (Anand et al., 2007)

Pharmacokinetics: Active Dose Over Time

t½ = ~4-6 hours (subcutaneous administration)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
15
Sequence
EVYVVAENQQGKSKA
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers
CAS: Not available (custom research peptide, no CAS registered for dimer)

Who Should Consider FGL (FG Loop Peptide)

  • Individuals seeking cognitive enhancement and memory support
  • Adults with age-related cognitive decline
  • Researchers studying neuroprotection and neuroplasticity
  • Post-stroke patients exploring recovery-adjunct peptides
  • Individuals with traumatic brain injury in recovery phase

Related Peptides

What Changed for FGL (FG Loop Peptide)

No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

Peptide Schedule Research TeamReviewed Apr 7, 20268 Citations

References

  1. [1]A synthetic neural cell adhesion molecule mimetic peptide promotes synaptogenesis and memory consolidation (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]A synthetic NCAM-derived peptide, FGL, protects hippocampal neurons from ischemic insult in vitro and in vivo (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]Tolerability, safety and pharmacokinetics of the FGLL peptide following intranasal administration in healthy volunteers (opens in a new tab)(n=24)PubMed (opens in a new tab)PubMed
  4. [4]An NCAM-derived FGF-receptor agonist, the FGL-peptide, induces neurite outgrowth and neuronal survival (opens in a new tab)PubMed (opens in a new tab)PubMed
  5. [5]The NCAM-derived peptide FGL mobilizes endogenous neural stem cells and promotes regenerative capacity after stroke (opens in a new tab)PubMed (opens in a new tab)PubMed
  6. [6]The neural cell adhesion molecule-derived peptide FGL facilitates long-term plasticity in the dentate gyrus in vivo (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Up to 24 months at -20°C, protected from light and moisture
After Reconstitution
Up to 21 days refrigerated at 2-8°C; do not freeze reconstituted solution
Temperature
-20°C lyophilized; 2-8°C (36-46°F) reconstituted

Frequently Asked Questions

From Dr. William Seeds' self-published Peptide Protocols, Volume 1. Not from any peer-reviewed study. The only human data is a single Phase I intranasal trial using 25-200 mg doses. No published human SC pharmacokinetic study exists. Whether 1-2 mg SC even reaches the CNS in meaningful amounts is genuinely unknown.

FGL (FG Loop Peptide) typically comes in 5mg or 10mg vials. Add 2mL of bacteriostatic water to the vial. Use the free calculator for exact syringe units based on your desired dose.

The half-life of FGL (FG Loop Peptide) is ~4-6 hours (subcutaneous administration). This determines how frequently you need to dose for consistent blood levels.

The seizure risk is the lead concern. In a mouse kindling model of epilepsy, FGL at 2 and 10 mg/kg subcutaneous lowered the stimulation threshold for generalized seizures (PMC3963124). This is not a theoretical flag. It is a published preclinical finding that directly contradicts casual use in anyone with a seizure history. The Phase I human data covers 24 volunteers receiving single intranasal doses of 25, 100, or 200 mg of FGL(L) (PMID 17375985). Two of eight subjects at the 200 mg dose reported brief nasal burning lasting less than 3 minutes. No ECG abnormalities, no vital sign changes, no laboratory parameter shifts across any dose group. That is reassuring for single-dose safety, but 8 days of observation in 24 people tells you almost nothing about chronic subcutaneous use. FGFR1 carries an oncogenesis concern. FGFR1 is amplified or mutated in roughly 5 to 10 percent of human cancers, including breast, lung, bladder, and endometrial malignancies. Sustained FGFR1 agonism could theoretically worsen any FGFR1-driven tumor. No cancer events appeared in the Phase I trial, but single-dose exposure is a poor test of this risk. Active malignancies are an absolute contraindication. Community side effects from the small Longecity user base include brain fog, mood dysregulation, and cognitive dulling, particularly in the first two weeks. These come from fewer than 30 total reports, so frequency estimates are not possible. An important caveat about community side effects: the subcutaneous doses people use (1 to 2 mg) may be far below CNS-effective concentrations. Allometric scaling of the animal doses (2 to 10 mg/kg in rats) translates to 140 to 700 mg for a 70 kg human. Both positive and negative community outcomes may be noise rather than real pharmacological signal. Injection site discomfort is mild and transient. Reconstitution can be tricky; FGL(L) dissolves slowly, and cloudy solutions with persistent particulate should be discarded. Contraindications: pregnancy and breastfeeding (no reproductive safety data). Seizure disorders or epilepsy history. Active brain tumors or CNS malignancies. Known hypersensitivity to NCAM-derived peptides. Children under 18. When to stop: any seizure-like symptoms including unusual head sensations, visual disturbances, or muscle twitching. Mood disruption persisting beyond one week. Any new cancer diagnosis.